Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors

dc.contributor.authorReddy, Nakita
dc.contributor.authorGirdhar, Letisha
dc.contributor.authorShungube, Mbongeni
dc.contributor.authorGouws, Arnoldus C.
dc.contributor.authorPeters, Byron K.
dc.contributor.authorRajbongsh, Kamal K.
dc.contributor.authorBaijnath, Sooraj
dc.contributor.authorMdanda, Sipho
dc.contributor.authorNtombela, Thandokuhle
dc.contributor.authorArumugam, Thilona
dc.contributor.authorBester, Linda A.
dc.contributor.authorSingh, Sanil D.
dc.contributor.authorChuturgoon, Anil
dc.contributor.authorArvidsson, Per I.
dc.contributor.authorMaguire, Glenn E. M.
dc.contributor.authorKruger, Hendrik G.
dc.contributor.authorGovender, Thavendran
dc.contributor.authorNaicker, Tricia
dc.date.accessioned2026-11-02T09:00:12Z
dc.date.issued2023-03
dc.description.abstractVirulent Enterobacterale strains expressing serine and metallo-β-lactamases (MBL) genes have emerged responsible for conferring resistance to hard-to-treat infectious diseases. One strategy that exists is to develop β-lactamase inhibitors to counter this resistance. Currently, serine β-lactamase inhibitors (SBLIs) are in therapeutic use. However, an urgent global need for clinical metallo-βlactamase inhibitors (MBLIs) has become dire. To address this problem, this study evaluated BP2, a novel beta-lactam-derived β-lactamase inhibitor, co-administered with meropenem. According to the antimicrobial susceptibility results, BP2 potentiates the synergistic activity of meropenem to a minimum inhibitory concentration (MIC) of ≤1 mg/L. In addition, BP2 is bactericidal over 24 h and safe to administer at the selected concentrations. Enzyme inhibition kinetics showed that BP2 had an apparent inhibitory constant (Ki app) of 35.3 µM and 30.9 µM against New Delhi Metallo-β-lactamase (NDM-1) and Verona Integron-encoded Metallo-β-lactamase (VIM-2), respectively. BP2 did not interact with glyoxylase II enzyme up to 500 µM, indicating specific (MBL) binding. In a murine infection model, BP2 co-administered with meropenem was efficacious, observed by the >3 log10 reduction in K. pneumoniae NDM cfu/thigh. Given the promising pre-clinical results, BP2 is a suitable candidate for further research and development as an (MBLI).
dc.description.sponsorshipThe South African National Research Foundation. The Technology Innovation Agency of South Africa. University of KwaZulu-Natal, College of Health Sciences.
dc.description.submitterPM2026
dc.facultyFaculty of Health Sciences
dc.identifier0000-0001-7860-1779
dc.identifier.citationReddy, N.; Girdhari, L.; Shungube, M.; Gouws, A.C.; Peters, B.K.; Rajbongshi, K.K.; Baijnath, S.; Mdanda, S.; Ntombela, T.; Arumugam, T.; et al. Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-βLactamase Inhibitors. Antibiotics 2023, 12, 633. https://doi.org/10.3390/ antibiotics12040633
dc.identifier.issn2079-6382 (online)
dc.identifier.other10.3390/antibiotics12040633
dc.identifier.urihttps://hdl.handle.net/10539/50259
dc.journal.titleAntibiotics
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofseriesVol. 12; Issue 633
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
dc.schoolSchool of Physiology
dc.subjectMetallo-β-lactamases
dc.subjectCarbapenem resistant Enterobacterales
dc.subjectCyclic amino acidic chelator
dc.subjectBP2
dc.subjectMurine thigh infection model
dc.subject.primarysdgSDG-3: Good health and well-being
dc.titleNeutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Reddy_Neutralizing_2023.pdf
Size:
2.97 MB
Format:
Adobe Portable Document Format
Description:
Main article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.43 KB
Format:
Item-specific license agreed upon to submission
Description: